183 related articles for article (PubMed ID: 31509117)
21. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
Zhang GC; Liu J; Yu XN; Deng Y; Sun Y; Liu TT; Dong L; Zhu CF; Shen XZ; Zhu JM; Weng SQ; Li Y
Adv Healthc Mater; 2020 Nov; 9(21):e2000650. PubMed ID: 33000919
[TBL] [Abstract][Full Text] [Related]
22. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
[TBL] [Abstract][Full Text] [Related]
24. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
25. Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy.
Ming Y; Li B; Fu R; Xing H; Liu Y; Duan D; Li Z; Li L; Ni R; Xu J; Li C; Xiang M; Song H; Chen J
J Nanosci Nanotechnol; 2021 Oct; 21(10):5075-5082. PubMed ID: 33875093
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
27. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Nour MA; Kheradmand F; Rasmi Y; Baradaran B
Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
[TBL] [Abstract][Full Text] [Related]
28. The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.
Zhang S; Gao W; Tang J; Zhang H; Zhou Y; Liu J; Chen K; Liu F; Li W; To SKY; Wong AST; Zhang XK; Zhou H; Zeng JZ
Theranostics; 2020; 10(3):1230-1244. PubMed ID: 31938062
[No Abstract] [Full Text] [Related]
29. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
30. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
31. Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor.
Li X; Yu H; Huang Y; Chen Y; Wang J; Xu L; Zhang F; Zhuge Y; Zou X
Biomed Pharmacother; 2020 Sep; 129():110512. PubMed ID: 32768982
[TBL] [Abstract][Full Text] [Related]
32. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
33. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
34. Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
Abdel Wahab AHA; Ayad EG; Abdulla MS; Sharada HM; Ashmawy AM
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2951-2958. PubMed ID: 34582667
[TBL] [Abstract][Full Text] [Related]
35. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
36. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
37. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
38. Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma.
Park W; Cho S; Ji J; Lewandowski RJ; Larson AC; Kim DH
Radiol Imaging Cancer; 2021 Jan; 3(1):e200006. PubMed ID: 33575658
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
